BackCancer Genetics Overview

Cancer Genetics Total Current Liabilities

Cancer Genetics's total current liabilities is $4.3M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$4.26M

Peer average

Loading

Cancer Genetics Total Current Liabilities History

Loading

Cancer Genetics vs. peers: Total Current Liabilities Comparison

Loading

Cancer Genetics Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Cancer Genetics (CGIX) FAQ

The latest total current liabilities for CGIX is $4.3M as of December 2020. Investors often review this figure alongside Cancer Genetics's historical trend and sector peers before judging valuation or financial health.

A total current liabilities figure of $4.3M for CGIX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting CGIX's total current liabilities ($4.3M), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Cancer Genetics's total current liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.